Semaglutide vs 5-Amino-1MQ
Side-by-side comparison of Semaglutide and 5-Amino-1MQ: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Semaglutide
5-Amino-1MQ
Semaglutide
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural…
Lowest listed price: $39.00 across 12 listings
Full Semaglutide profile5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to…
Lowest listed price: $29.99 across 14 listings
Full 5-Amino-1MQ profileSide-by-side comparison
| Attribute | Semaglutide | 5-Amino-1MQ |
|---|---|---|
| Category | Metabolic & Weight Loss | Weight Loss |
| Research Stage | FDA Approved | Preclinical |
| Mechanism of Action | GLP-1 Receptor Agonism and cAMP Signaling Semaglutide binds to the GLP-1 receptor (GLP-1R), a class B G-protein coupled receptor expressed on pancreatic beta cells, hypothalamic neurons, gastric smooth muscle, cardiac myocytes, and other tissues. Upon binding,… | 5-Amino-1MQ works by inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the nitrogen of nicotinamide (vitamin B3 amide), producing 1-methylnicotinamide (1-MNA) and… |
| Half-Life | ~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification | ~6–12 hours (oral) |
| Typical Dose Range | Diabetes (Ozempic): 250-1000 mcg weekly; Weight management (Wegovy): 2400 mcg weekly (after 16-week titration); Oral (Rybelsus): 3-14 mg daily | 50 mg - 150 mg daily (oral or injection) |
| Dosing Frequency | Once weekly subcutaneous injection | Once daily oral |
| Administration | Subcutaneous (weekly), Oral (daily) | Oral |
| Side Effects | Nausea (especially at initiation — dose-dependent), vomiting, diarrhea, constipation, abdominal pain, decreased appetite (therapeutic effect), headache, fatigue, dizziness. Rare: pancreatitis, gallbladder issues, thyroid C-cell tumors (rodent studies).… | The side effect profile of 5-amino-1MQ in humans is not documented because there are no human clinical trials. Rodent studies report generally good tolerability at doses producing metabolic and muscle benefits, without obvious signs of hepatotoxicity,… |
| Molecular Weight | 4113.6 Da | 159.21 g/mol |
| Common Vial Sizes | 3mg, 5mg, 10mg | 50mg capsules, 100mg capsules |
Price History
4 data points- OF
- Half Nattys
- Ion Peptide
- Disguised Alpha
Price History
5 data points- OF
- BM
- Half Nattys
- Ion Peptide
- Disguised Alpha
- RC
- LB
Semaglutide: potential benefits
- Mean body weight reduction of 14.9% at 68 weeks in STEP 1 trial (PMID: 33567185)
- Sustained weight loss of ~15% (-15.2%) maintained through 104 weeks in STEP 5 trial (PMID: 36216945)
- 20% relative reduction in major adverse cardiovascular events (HR 0.80) in the SELECT trial (PMID: 37952131)
- HbA1c reduction of 1.5-1.8% in type 2 diabetes (SUSTAIN program)
- Reduction in systemic inflammation (lower hs-CRP) observed in SELECT
- Available in both subcutaneous (weekly) and oral (daily) formulations
- Improved cardiometabolic risk factors including blood pressure and lipid profile
5-Amino-1MQ: potential benefits
- Enhanced fat metabolism and weight loss
- Increased NAD+ levels in adipose tissue
- Improved cellular energy production
- Anti-aging properties via sirtuin activation
Frequently asked
What's the difference between Semaglutide and 5-Amino-1MQ?
Semaglutide is a metabolic & weight loss that glp-1 receptor agonism and camp signaling semaglutide binds to the glp-1 receptor (glp-1r), a class b g-protein coupled receptor expressed on pancreatic beta cells, hypothalamic…. 5-Amino-1MQ is a weight loss that 5-amino-1mq works by inhibiting nicotinamide n-methyltransferase (nnmt), an enzyme that catalyzes the transfer of a methyl group from s-adenosyl-l-methionine (sam) to the nitrogen…. The two differ in mechanism, half-life (~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification vs ~6–12 hours (oral)), and typical dose range.
Which has the longer half-life, Semaglutide or 5-Amino-1MQ?
Semaglutide has a half-life of ~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification. 5-Amino-1MQ has a half-life of ~6–12 hours (oral). Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Semaglutide or 5-Amino-1MQ?
Lowest listed price on BodyHackGuide: Semaglutide from $39.00, 5-Amino-1MQ from $29.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack Semaglutide and 5-Amino-1MQ?
Stacking depends on mechanism overlap, safety profile, and goals. Semaglutide and 5-Amino-1MQ should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Semaglutide or 5-Amino-1MQ
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.